Tests a lipid decision-support system for stroke patients taking evolocumab
Tests a computer tool guiding cholesterol treatment in adults after ischemic stroke or TIA.
Plain-language title generated from the registry record
Registry title: Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a stroke caused by a blocked blood vessel (not from the heart) or a mini-stroke (TIA) in the last 3 months and are prescribed Evolocumab.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Non-cardioembolic ischemic stroke or TIA within the 3 months before screening
- Earlier treatment
- Cannot have used Evolocumab or another PCSK9 inhibitor in the 6 months before screening
Main reasons for not taking part
- Bleeding in the brain, such as cerebral hemorrhage or subarachnoid hemorrhage
- Other brain diseases seen on baseline head CT or MRI, such as vascular malformations, tumors or abscesses
- Silent cerebral infarction without signs and symptoms
- Taking part in another drug or device trial in the past 3 months or now
- Life expectancy under 12 months
Read by machine on 12 November 2026.
Where in China
- Beijing Tiantan HospitalBeijing, ChinaContact: Jie XuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07143149
- Record updated
- 2 January 2026
- Original description
This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.Read full original descriptionShow less
Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.
Inclusion: Age≥18 years as of the screening date; Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date; Prescribed Evolocumab at physician's discretion; Signed informed consent.
Exclusion: Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date; Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date; Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc; Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis); Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders; Silent cerebral infarction without signs and symptoms; Life expectancy <12 months or unable to complete the research for other reasons as of the screening date; Refusal to participate in the enrollment survey.